Skip to main content
SpringerLink
Log in

Erlotinib therapy based on EGFR mutation status cost effective

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2014 euros

Reference

  • Schremser K, et al. Cost-Effectiveness of an Individualized First-Line Treatment Strategy Offering Erlotinib Based on EGFR Mutation Testing in Advanced Lung Adenocarcinoma Patients in Germany. PharmacoEconomics : 17 Jun 2015. Available from: URL: http://doi.org/10.1007/s40273-015-0305-8

    PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Erlotinib therapy based on EGFR mutation status cost effective. PharmacoEcon Outcomes News 731, 15 (2015). https://doi.org/10.1007/s40274-015-2244-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-015-2244-1

Search

Navigation